Brolucizumab 治疗 nAMD 的眼内炎症、视网膜血管炎及视网膜闭塞相关事件风险:HAWK 与 HARRIER 事后分析
本事后分析由独立安全审查委员会复核 HAWK 与 HARRIER 两项 3 期随机双盲试验中研究者报告的眼内炎症、眼内炎及视网膜动脉闭塞病例,共纳入 1817 例未治疗的活动性 nAMD 患者。Brolucizumab 组明确/可能药物相关 IOI 发生率为 4.6%,其中 IOI+血管炎为 3.3%、IOI+血管炎+闭塞为 2.1%,至少中度视力下降发生率为 0.74%;Aflibercept 组 IOI 发生率为 1.1%,至少中度视力下降为 0.14%。
要点
- Brolucizumab 组明确/可能 IOI 发生率为 4.6%,Aflibercept 组为 1.1%。
- IOI 合并视网膜血管炎及闭塞者视力下降风险更高。
- 多数 IOI 相关事件发生于首次注射后 6 个月内。
核心结论
- Brolucizumab 注射后 IOI 病例中可见视网膜血管炎伴或不伴视网膜血管闭塞,并伴随视力下降风险。
研究设计与样本
- 对两项 2 年、双盲、多中心、阳性对照随机 3 期试验(HAWK 与 HARRIER)数据的事后分析。
- 共纳入 1817 例研究眼为未治疗活动性脉络膜新生血管的 nAMD 患者。
- 独立安全审查委员会复核研究者报告的 IOI、视网膜动脉闭塞及眼内炎病例,由至少 2 名阅片者详细审阅后集体裁定。
主要发现
- 明确/可能 IOI 发生率为 4.6%,其中 IOI+血管炎为 3.3%,IOI+血管炎+闭塞为 2.1%。
- IOI 眼中至少中度视力下降(≥15 ETDRS 字母)共 8 例,发生率为 0.74%,其中 7 例见于 IOI+血管炎+闭塞眼。
- 8 例视力下降病例中,5 例首次 IOI 相关事件发生于首次 brolucizumab 注射后 3 个月内,7 例发生于 6 个月内。
- Aflibercept 组 IOI 发生率为 1.1%,至少中度视力下降发生率为 0.14%。
关键数值与推荐
- Brolucizumab 组明确/可能 IOI 发生率 4.6%(IOI+血管炎 3.3%;IOI+血管炎+闭塞 2.1%)。
- Brolucizumab 组 IOI 眼中至少中度视力下降(≥15 ETDRS 字母)发生率 0.74%。
- Aflibercept 组 IOI 发生率 1.1%,至少中度视力下降发生率 0.14%。
临床怎么用
- 临床评估 nAMD 患者使用 brolucizumab 的风险与获益时,应关注 IOI、视网膜血管炎及血管闭塞相关事件。
- 注射后早期尤其 6 个月内应警惕 IOI 相关事件及视力下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age-related macular degeneration (nAMD). DESIGN: A post hoc analysis of a subset of data from two 2-year, double-masked, multicenter, active-controlled randomized phase 3 trials (NCT02307682, NCT02434328). PARTICIPANTS: Patients (N = 1817) with untreated, active choroidal neovascularization due to age-related macular degeneration in the study eye were randomized and treated in HAWK/HARRIER. The SRC reviewed data from cases of investigator-reported IOI (60/1088 brolucizumab-treated eyes; 8/729 aflibercept-treated eyes). METHODS: The SRC received details and images (color fundus photography, fluorescein angiography, and OCT) for all investigator-determined cases of IOI, retinal arterial occlusion, and endophthalmitis. Cases were reviewed in detail by ≥2 readers, then adjudicated by the SRC as a group. MAIN OUTCOME MEASURES: Within this patient subset: incidence of IOI, signs and incidence of retinal vasculitis and/or retinal vascular occlusion, and visual acuity loss; time since first brolucizumab injection to IOI event onset; and frequency of visual acuity loss after brolucizumab injection by time of first IOI event onset. RESULTS: Fifty brolucizumab-treated eyes were considered to have definite/probable drug-related events within the spectrum of IOI, retinal vasculitis, and/or vascular occlusion. On the basis of these cases, incidence of definite/probable IOI was 4.6% (IOI + vasculitis, 3.3%; IOI + vasculitis + occlusion, 2.1%). There were 8 cases (incidence 0.74%) of at least moderate visual acuity loss (≥15 ETDRS letters) in eyes with IOI (7 in eyes with IOI + vasculitis + occlusion). Of the 8 cases, 5 experienced their first IOI-related event within 3 months of the first brolucizumab injection (increasing to 7/8 within 6 months). Incidence of IOI in aflibercept-treated eyes was 1.1%, with at least moderate visual acuity loss in 0.14%. CONCLUSIONS: This analysis of IOI cases after brolucizumab injection identified signs of retinal vasculitis with or without retinal vascular occlusion and an associated risk of visual acuity loss. The findings will help physicians to evaluate the risks and benefits of brolucizumab treatment for nAMD.
引用
- Monés J, Srivastava SK, Jaffe GJ, et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2020. PMID: 33207259. doi:10.1016/j.ophtha.2020.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。